In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular (CV) targets; however, in patients with CKD, the previous guidelines [5] recommended the use of repaglinide or dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), together with insulin therapy, with basal insulin (BI) at onset and progressing later to basal-bolus (BB) therapy. The gene discussed is GLP1R; the disease is chronic kidney disease.